Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia

doi:10.1182/bloodadvances.2021005164

. 2021 Dec 14;5(23):5215-5219.

doi: 10.1182/bloodadvances.2021005164.

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia

Affiliations

¹ Department of Pediatrics.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and.
³ Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX.

PMID: 34592761
PMCID: PMC9153013
DOI: 10.1182/bloodadvances.2021005164

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia

David McCall et al. Blood Adv. 2021.

. 2021 Dec 14;5(23):5215-5219.

doi: 10.1182/bloodadvances.2021005164.

Authors

Affiliations

¹ Department of Pediatrics.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and.
³ Department of Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX.

PMID: 34592761
PMCID: PMC9153013
DOI: 10.1182/bloodadvances.2021005164

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
Survival from start of gilteritinib.

See this image and copyright information in PMC

Cited by

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li HT, Liang G, Leong R, Brown PA, Kaplan J, Schafer ES, Slone T, Pauly M, Chang BH, Stieglitz E, Wayne AS, Hijiya N, Bhojwani D. Verma A, et al. Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496. Cancers (Basel). 2024. PMID: 38339248 Free PMC article.
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.
Al-Antary ET, Gupte A, Ravindranath Y. Al-Antary ET, et al. Indian J Pediatr. 2024 Feb;91(2):176-183. doi: 10.1007/s12098-023-04741-3. Epub 2023 Jul 14. Indian J Pediatr. 2024. PMID: 37450248 Review.
Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.
Li J, Liu L, Zhang R, Wan Y, Gong X, Zhang L, Yang W, Chen X, Zou Y, Chen Y, Guo Y, Ruan M, Zhu X. Li J, et al. Br J Haematol. 2022 Sep;198(6):1041-1050. doi: 10.1111/bjh.18354. Epub 2022 Jul 25. Br J Haematol. 2022. PMID: 35880261 Free PMC article.
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui CH, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD. Inaba H, et al. Clin Cancer Res. 2022 Jun 13;28(12):2536-2546. doi: 10.1158/1078-0432.CCR-21-4450. Clin Cancer Res. 2022. PMID: 35344039 Free PMC article.
Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Czogała M, Czogała W, Pawińska-Wąsikowska K, Książek T, Bukowska-Strakova K, Sikorska-Fic B, Łaguna P, Fałkowska A, Drabko K, Muszyńska-Rosłan K, Krawczuk-Rybak M, Kozłowska M, Irga-Jaworska N, Zielezińska K, Urasiński T, Bartoszewicz N, Styczyński J, Skalska-Sadowska J, Wachowiak J, Rodziewicz-Konarska A, Kałwak K, Ciebiera M, Chaber R, Mizia-Malarz A, Chodała-Grzywacz A, Karolczyk G, Bobeff K, Młynarski W, Mycko K, Badowska W, Tomaszewska R, Szczepański T, Machnik K, Zamorska N, Balwierz W, Skoczeń S. Czogała M, et al. Cancers (Basel). 2023 Sep 14;15(18):4557. doi: 10.3390/cancers15184557. Cancers (Basel). 2023. PMID: 37760526 Free PMC article.

References

1. Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60(5):728-733. - PMC - PubMed
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021;71(4):359]. CA Cancer J Clin. 2021;71(1):7-33. - PubMed
1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565. - PMC - PubMed
1. Kaspers GJ, Zimmermann M, Reinhardt D, et al. . Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607. - PubMed
1. Meshinchi S, Alonzo TA, Stirewalt DL, et al. . Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60(5):728-733. - PMC - PubMed

[2] Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60(5):728-733. - PMC - PubMed

[3] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021;71(4):359]. CA Cancer J Clin. 2021;71(1):7-33. - PubMed

[4] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 [published correction appears in CA Cancer J Clin. 2021;71(4):359]. CA Cancer J Clin. 2021;71(1):7-33. - PubMed

[5] Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565. - PMC - PubMed

[6] Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565. - PMC - PubMed

[7] Kaspers GJ, Zimmermann M, Reinhardt D, et al. . Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607. - PubMed

[8] Kaspers GJ, Zimmermann M, Reinhardt D, et al. . Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607. - PubMed

[9] Meshinchi S, Alonzo TA, Stirewalt DL, et al. . Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661. - PMC - PubMed

[10] Meshinchi S, Alonzo TA, Stirewalt DL, et al. . Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia

Affiliations

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia

Authors

Affiliations

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous